These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 38306059)
1. Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy. Lidonnici D; Brambilla P; Ravasio R; Zozulya-Weidenfeller A; Beiderbeck A; van Aswegen M; Oliveira R; Sansone VA J Neuromuscul Dis; 2024; 11(2):411-423. PubMed ID: 38306059 [TBL] [Abstract][Full Text] [Related]
2. Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey. Díaz-Manera J; Urtizberea JA; Schey C; Kole A; von Gallwitz P; Whiting A; Foerster D; Zozulya-Weidenfeller A Neuromuscul Disord; 2023 Feb; 33(2):208-217. PubMed ID: 36706619 [TBL] [Abstract][Full Text] [Related]
3. Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel. Chapman AM; Schurer M; Weijers L; Omar A; Lee H; Weidenfeller AZ; Ellis C; Sonecha S; Schneider-Gold C BMC Neurol; 2021 Dec; 21(1):467. PubMed ID: 34852780 [TBL] [Abstract][Full Text] [Related]
5. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1. Salguero-Bodes R; Ruiz-Curiel A; Palomino-Doza J; Valverde-Gómez M; Domínguez-González C; Arribas-Ynsaurriaga F Rev Esp Cardiol (Engl Ed); 2021 Nov; 74(11):986-987. PubMed ID: 34120884 [No Abstract] [Full Text] [Related]
7. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia. D'Mello S; Shum L Eur J Hosp Pharm; 2016 Nov; 23(6):359-363. PubMed ID: 31156883 [TBL] [Abstract][Full Text] [Related]
8. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. Stunnenberg BC; Woertman W; Raaphorst J; Statland JM; Griggs RC; Timmermans J; Saris CG; Schouwenberg BJ; Groenewoud HM; Stegeman DF; van Engelen BG; Drost G; van der Wilt GJ BMC Neurol; 2015 Mar; 15():43. PubMed ID: 25880166 [TBL] [Abstract][Full Text] [Related]
9. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. Statland JM; Bundy BN; Wang Y; Rayan DR; Trivedi JR; Sansone VA; Salajegheh MK; Venance SL; Ciafaloni E; Matthews E; Meola G; Herbelin L; Griggs RC; Barohn RJ; Hanna MG; JAMA; 2012 Oct; 308(13):1357-65. PubMed ID: 23032552 [TBL] [Abstract][Full Text] [Related]
10. Treatment of myotonia with antiarrhythmic drugs. Kwieciński H; Ryniewicz B; Ostrzycki A Acta Neurol Scand; 1992 Oct; 86(4):371-5. PubMed ID: 1455983 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654 [TBL] [Abstract][Full Text] [Related]
19. Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia. van den Berg S; van der Wel V; de Visser SJ; Stunnenberg BC; Timmers L; van der Ree MH; Postema PG; Hollak CEM Value Health; 2021 Jul; 24(7):925-929. PubMed ID: 34243835 [TBL] [Abstract][Full Text] [Related]
20. Non-dystrophic myotonias: clinical and mutation spectrum of 70 German patients. Vereb N; Montagnese F; Gläser D; Schoser B J Neurol; 2021 May; 268(5):1708-1720. PubMed ID: 33263785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]